Literature DB >> 23677525

Anxiolytic action of pterostilbene: involvement of hippocampal ERK phosphorylation.

Md Al Rahim1, Agnes M Rimando, Kalpten Silistreli, Abir T El-Alfy.   

Abstract

Pterostilbene, a natural analog of resveratrol, has diverse health-beneficial properties. However, the neurological activities of this compound are largely unexplored. Here, we report that pterostilbene shows anxiolytic-like actions by down-regulating phosphorylated levels of extracellular regulated kinases in the hippocampus of mice. Adult male mice administered pterostilbene (1-10 mg/kg, p. o.) were subjected to the elevated plus maze test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by increases in % permanence time and number of open arm entries. The locomotor activity of the animals was unaffected at all doses. Western blot analysis revealed a decrease in both extracellular regulated kinase 1 and extracellular regulated kinase 2 phosphorylation in hippocampal homogenates from mice treated with 1 and 2 mg/kg pterostilbene. Moreover, pterostilbene was detected in the plasma and brains of mice following single oral administration. Anxiolytic activity was not observed at the higher doses (5 and 10 mg/kg). However, no impairment of motor function was observed either, suggesting a favorable safety index for the compound. These results suggest that pterostilbene has the potential for therapeutic drug development for anxiety disorders. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23677525     DOI: 10.1055/s-0032-1328553

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  7 in total

1.  HO-1 Signaling Activation by Pterostilbene Treatment Attenuates Mitochondrial Oxidative Damage Induced by Cerebral Ischemia Reperfusion Injury.

Authors:  Yang Yang; Jiayi Wang; Yue Li; Chongxi Fan; Shuai Jiang; Lei Zhao; Shouyin Di; Zhenlong Xin; Bodong Wang; Guiling Wu; Xia Li; Zhiqing Li; Xu Gao; Yushu Dong; Yan Qu
Journal:  Mol Neurobiol       Date:  2015-05-16       Impact factor: 5.590

2.  Effect of Pterostilbene, a Natural Analog of Resveratrol, on the Activity of some Antiepileptic Drugs in the Acute Seizure Tests in Mice.

Authors:  Dorota Nieoczym; Katarzyna Socała; Piotr Jedziniak; Elżbieta Wyska; Piotr Wlaź
Journal:  Neurotox Res       Date:  2019-03-15       Impact factor: 3.911

Review 3.  A Review of Plant Extracts and Plant-Derived Natural Compounds in the Prevention/Treatment of Neonatal Hypoxic-Ischemic Brain Injury.

Authors:  Hadi Mohsenpour; Mirko Pesce; Antonia Patruno; Azam Bahrami; Pardis Mohammadi Pour; Mohammad Hosein Farzaei
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

4.  Anticonvulsant Activity of Pterostilbene in Zebrafish and Mouse Acute Seizure Tests.

Authors:  Dorota Nieoczym; Katarzyna Socała; Kinga Gawel; Camila V Esguerra; Elżbieta Wyska; Piotr Wlaź
Journal:  Neurochem Res       Date:  2019-01-28       Impact factor: 3.996

5.  Dorsal Hippocampus ERK2 Signaling Mediates Anxiolytic-Related Behavior in Male Rats.

Authors:  Jorge A Sierra-Fonseca; Lyonna F Parise; Francisco J Flores-Ramirez; Eden H Robles; Israel Garcia-Carachure; Sergio D Iñiguez
Journal:  Chronic Stress (Thousand Oaks)       Date:  2019-12-24

Review 6.  Recent Advances in Synthesis, Bioactivity, and Pharmacokinetics of Pterostilbene, an Important Analog of Resveratrol.

Authors:  Yeju Liu; Yuyang You; Juan Lu; Xi Chen; Zhihong Yang
Journal:  Molecules       Date:  2020-11-06       Impact factor: 4.411

7.  Anticonvulsant effect of pterostilbene and its influence on the anxiety- and depression-like behavior in the pentetrazol-kindled mice: behavioral, biochemical, and molecular studies.

Authors:  Dorota Nieoczym; Katarzyna Socała; Agnieszka Zelek-Molik; Mateusz Pieróg; Katarzyna Przejczowska-Pomierny; Małgorzata Szafarz; Elżbieta Wyska; Irena Nalepa; Piotr Wlaź
Journal:  Psychopharmacology (Berl)       Date:  2021-08-01       Impact factor: 4.415

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.